한글목차

옵디보(니볼루맙) 시장 규모는 최근 현저한 성장을 이루고 있습니다. 2025년 834만 달러에서 2026년에는 901만 달러에 이르고, CAGR 8.1%로 성장할 전망입니다. 지난 몇 년간의 성장은 PD-1 억제제의 승인, 전 세계 암 부담 증가, 화학요법의 한계, 강력한 임상시험 결과, 종양 전문의의 면역요법 채택에 기인하는 것으로 보입니다.

옵디보(니볼루맙) 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 1,213만 달러에 이르고, CAGR은 7.7%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 새로운 종양학 적응증으로의 확대, 병용요법 프로토콜 증가, 바이오마커에 기반한 환자 선택 확대, 암 진단율 증가, 종양학 의료비 증가 등을 꼽을 수 있습니다. 예측 기간 동안 주요 동향으로는 면역관문억제제 사용 확대, 병용 면역요법 요법 도입 증가, PD-1 기반 암 치료의 성장, 여러 암 적응증에 대한 사용 증가, 장기 생존율에 대한 관심 증가 등이 있습니다.

비소세포폐암(NSCLC)의 발생률 증가는 향후 몇 년간 옵디보(니볼루맙) 시장의 성장을 견인할 것으로 예측됩니다. 비소세포폐암은 폐암 중 가장 흔한 유형으로 전체 폐암의 약 85%를 차지합니다. 비소세포폐암의 발생률 증가는 주로 흡연, 환경오염물질 노출, 유전자 돌연변이, 암 가족력 등의 요인에 기인합니다. 옵디보는 면역세포의 PD-1 수용체를 억제하여 암세포를 인식하고 공격하는 신체의 면역반응을 강화하는 작용을 합니다. 예를 들어, 2024년 미국 암협회(American Cancer Society)는 미국에서 23만 4,580건의 새로운 폐암 사례가 보고되었으며, 그 중 80%가 비소세포폐암이라고 발표했습니다. 이는 2023년 23만 8,340명 대비 증가한 수치로, 비소세포폐암 발생률 증가가 옵디보(니볼루맙) 시장의 성장을 견인하고 있습니다.

옵디보(니볼루맙) 시장의 주요 기업들은 치료 효과 향상, 내성 극복, 여러 암종에 대한 적용 확대를 위한 첨단 병용요법 개발에 집중하고 있습니다. 병용요법은 옵디보(니볼루맙)를 화학요법 등 다른 약제와 병용하여 진행성 암 환자에게 보다 종합적인 접근법을 제공하는 치료법입니다. 예를 들어, 2024년 10월 미국 식품의약국(FDA)은 EGFR 또는 ALK 변이가 없는 절제 가능한 비소세포폐암 성인 환자에게 수술 전 보조요법으로 옵디보(니볼루맙)와 백금제제 이중화학요법 병용요법을 승인했습니다. 이어 수술 후 보조요법으로 니볼루맙 단독요법이 승인되었습니다. 이번 승인으로 옵디보는 수술 전후에 투여할 수 있게 되어 적격 환자의 치료 결과를 개선할 수 있게 됐습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 한국 시장

제17장 서유럽 시장

제18장 영국 시장

제19장 독일 시장

제20장 프랑스 시장

제21장 동유럽 시장

제22장 북미 시장

제23장 미국 시장

제24장 캐나다 시장

제25장 남미 시장

제26장 중동 시장

제27장 아프리카 시장

제28장 시장 규제 상황과 투자환경

제29장 경쟁 구도와 기업 개요

제30장 세계 시장 경쟁 벤치마킹과 대시보드

제31장 주요 인수합병(M&A)

제32장 시장 잠재력이 높은 국가, 부문, 전략

제33장 부록

영문목차

Opdivo (nivolumab) is a prescription drug classified as an immune checkpoint inhibitor that specifically targets programmed death-1 (PD-1) receptors. It is an immunotherapy used to treat various cancers by boosting the body's immune system to recognize and destroy cancer cells.

The main forms of Opdivo (nivolumab) available in the market are 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml. The 40 mg/4 ml dose is a lower concentration intended for patients who require smaller doses, often used in specific treatment protocols or for lower-weight patients. The drug is available in various forms, including injections and solutions, and is used across demographics such as adults and pediatric patients. Its applications include melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancers. End-users include hospitals, clinics, and other healthcare facilities.

Tariffs have impacted the opdivo market by increasing costs related to imported biologic manufacturing inputs, monoclonal antibody processing equipment, and cold-chain logistics. These pressures are more visible in hospital oncology settings where biologics form a major cost component. Regions such as north america and europe experience pricing sensitivity due to biologic import reliance. At the same time, tariffs are encouraging regional biologics manufacturing investments. This is improving supply resilience and reducing long-term dependency on cross-border sourcing.

The opdivo (nivolumab) market research report is one of a series of new reports from The Business Research Company that provides opdivo (nivolumab) market statistics, including opdivo (nivolumab) industry global market size, regional shares, competitors with a opdivo (nivolumab) market share, detailed opdivo (nivolumab) market segments, market trends and opportunities, and any further data you may need to thrive in the opdivo (nivolumab) industry. This opdivo (nivolumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The opdivo (nivolumab) market size has grown strongly in recent years. It will grow from $8.34 million in 2025 to $9.01 million in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to approval of pd-1 inhibitors, rising global cancer burden, limitations of chemotherapy, strong clinical trial outcomes, oncologist adoption of immunotherapy.

The opdivo (nivolumab) market size is expected to see strong growth in the next few years. It will grow to $12.13 million in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to expansion into new oncology indications, growth of combination therapy protocols, increasing biomarker based patient selection, rising cancer diagnosis rates, increased oncology healthcare spending. Major trends in the forecast period include expanding use of immune checkpoint inhibitors, rising adoption of combination immunotherapy regimens, growth in pd-1 based cancer treatments, increased use across multiple cancer indications, focus on long term survival outcomes.

The increasing incidence of non-small cell lung cancer (NSCLC) is expected to drive the growth of the Opdivo (nivolumab) market in the coming years. NSCLC is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases. The rising incidence of NSCLC is primarily due to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo works by blocking the PD-1 receptor on immune cells, enhancing the body's immune response to recognize and attack cancer cells. For example, in 2024, the American Cancer Society, a US-based health organization, reported 234,580 new lung cancer cases in the United States, with 80% being NSCLC. This marks an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Therefore, the rising incidence of NSCLC is driving the Opdivo (nivolumab) market.

Leading companies in the Opdivo (nivolumab) market are focusing on developing advanced combination therapies to improve treatment efficacy, overcome resistance, and expand applications across multiple cancer types. Combination therapy involves using Opdivo (nivolumab) alongside other agents, such as chemotherapy, to provide a more comprehensive approach for patients with advanced cancer. For instance, in October 2024, the US Food and Drug Administration approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment, followed by single-agent nivolumab as adjuvant therapy after surgery, for adults with resectable NSCLC without known EGFR or ALK mutations. This approval allows Opdivo to be administered both before and after surgery, enhancing therapeutic outcomes for eligible patients.

In June 2024, I-Mab, a US-based biotechnology company developing innovative cancer immunotherapies, entered a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate the bispecific antibody givastomig. Through this partnership, I-Mab plans to assess its investigational Claudin 18.2 X 4-1BB bispecific antibody, givastomig, in combination with Opdivo (nivolumab) and standard chemotherapy regimens (FOLFOX or CAPOX) as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers. Bristol Myers Squibb, a US-based pharmaceutical company, manufactures Opdivo (nivolumab).

Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical

North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the opdivo (nivolumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The opdivo (nivolumab) market consists of sales of monotherapy and combination therapy. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Opdivo (nivolumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses opdivo (nivolumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for opdivo (nivolumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The opdivo (nivolumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: 40 mg/4 mL; 100 mg/10 mL; 240 mg/24 mL
• 2) By Dosage: Injection; Solution; Other Dosages
• 3) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma of the Head and Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
• 4) By End-User: Hospitals; Clinics; Other End Users
• Companies Mentioned: Bristol-Myers Squibb; Ono Pharmaceutical
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Opdivo (nivolumab) Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Opdivo (nivolumab) Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Opdivo (nivolumab) Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Opdivo (nivolumab) Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Artificial Intelligence & Autonomous Intelligence
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Sustainability, Climate Tech & Circular Economy
• 4.2. Major Trends
  • 4.2.1 Expanding Use Of Immune Checkpoint Inhibitors
  • 4.2.2 Rising Adoption Of Combination Immunotherapy Regimens
  • 4.2.3 Growth In Pd-1 Based Cancer Treatments
  • 4.2.4 Increased Use Across Multiple Cancer Indications
  • 4.2.5 Focus On Long Term Survival Outcomes

5. Opdivo (nivolumab) Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Oncology Clinics
• 5.3 Cancer Treatment Centers
• 5.4 Specialty Pharmacies
• 5.5 Research Institutes

6. Opdivo (nivolumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Opdivo (nivolumab) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Opdivo (nivolumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Opdivo (nivolumab) Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Opdivo (nivolumab) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Opdivo (nivolumab) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Opdivo (nivolumab) Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Opdivo (nivolumab) Market Segmentation

• 9.1. Global Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL
• 9.2. Global Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Injection, Solution, Other Dosages
• 9.3. Global Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications
• 9.4. Global Opdivo (nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Other End Users

10. Opdivo (nivolumab) Market Regional And Country Analysis

• 10.1. Global Opdivo (nivolumab) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Opdivo (nivolumab) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Opdivo (nivolumab) Market

• 11.1. Asia-Pacific Opdivo (nivolumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Opdivo (nivolumab) Market

• 12.1. China Opdivo (nivolumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Opdivo (nivolumab) Market

• 13.1. India Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Opdivo (nivolumab) Market

• 14.1. Japan Opdivo (nivolumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Opdivo (nivolumab) Market

• 15.1. Australia Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. South Korea Opdivo (nivolumab) Market

• 16.1. South Korea Opdivo (nivolumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 16.2. South Korea Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. Western Europe Opdivo (nivolumab) Market

• 17.1. Western Europe Opdivo (nivolumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. Western Europe Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. UK Opdivo (nivolumab) Market

• 18.1. UK Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Germany Opdivo (nivolumab) Market

• 19.1. Germany Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. France Opdivo (nivolumab) Market

• 20.1. France Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Eastern Europe Opdivo (nivolumab) Market

• 21.1. Eastern Europe Opdivo (nivolumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 21.2. Eastern Europe Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. North America Opdivo (nivolumab) Market

• 22.1. North America Opdivo (nivolumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 22.2. North America Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. USA Opdivo (nivolumab) Market

• 23.1. USA Opdivo (nivolumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 23.2. USA Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Canada Opdivo (nivolumab) Market

• 24.1. Canada Opdivo (nivolumab) Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 24.2. Canada Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. South America Opdivo (nivolumab) Market

• 25.1. South America Opdivo (nivolumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 25.2. South America Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Middle East Opdivo (nivolumab) Market

• 26.1. Middle East Opdivo (nivolumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Middle East Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Africa Opdivo (nivolumab) Market

• 27.1. Africa Opdivo (nivolumab) Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 27.2. Africa Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Opdivo (nivolumab) Market Regulatory and Investment Landscape

29. Opdivo (nivolumab) Market Competitive Landscape And Company Profiles

• 29.1. Opdivo (nivolumab) Market Competitive Landscape And Market Share 2024
  • 29.1.1. Top 10 Companies (Ranked by revenue/share)
• 29.2. Opdivo (nivolumab) Market - Company Scoring Matrix
  • 29.2.1. Market Revenues
  • 29.2.2. Product Innovation Score
  • 29.2.3. Brand Recognition
• 29.3. Opdivo (nivolumab) Market Company Profiles
  • 29.3.1. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 29.3.2. Ono Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis

30. Global Opdivo (nivolumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Opdivo (nivolumab) Market

32. Opdivo (nivolumab) Market High Potential Countries, Segments and Strategies

• 32.1 Opdivo (nivolumab) Market In 2030 - Countries Offering Most New Opportunities
• 32.2 Opdivo (nivolumab) Market In 2030 - Segments Offering Most New Opportunities
• 32.3 Opdivo (nivolumab) Market In 2030 - Growth Strategies
  • 32.3.1 Market Trend Based Strategies
  • 32.3.2 Competitor Strategies

33. Appendix

• 33.1. Abbreviations
• 33.2. Currencies
• 33.3. Historic And Forecast Inflation Rates
• 33.4. Research Inquiries
• 33.5. The Business Research Company
• 33.6. Copyright And Disclaimer